Infection with Human Papilloma Virus (HPV) and risk of subsites within the oral cancer.


Journal

Cancer epidemiology
ISSN: 1877-783X
Titre abrégé: Cancer Epidemiol
Pays: Netherlands
ID NLM: 101508793

Informations de publication

Date de publication:
12 2021
Historique:
received: 06 07 2021
revised: 25 08 2021
accepted: 27 08 2021
pubmed: 13 9 2021
medline: 15 12 2021
entrez: 12 9 2021
Statut: ppublish

Résumé

The aim of this study was to investigate the relationship between high-risk genotypes of Human Papilloma Virus (HPV) and cancer of different subsites of the oral cavity. A pooled analysis of five studies included on the International Head and Neck Cancer Epidemiology (INHANCE) Consortium was conducted. HPV 16 and HPV 18 were considered. Adjusted odds ratios (ORs) and corresponding 95 % confidence intervals (CIs) for HPV and each oral cavity subsites were simultaneously estimated using multinomial logistic regression models. The analysis included 1157 cases and 3272 controls. This study showed a slightly higher prevalence of HPV infection among oral cancer cases than controls. In particular, an increased risk of other and not otherwise specified (NOS) sites within the oral cavity, oral tongue, palate and floor of mouth cancer was observed for overall HPV16 positivity (OR = 1.66, 95 % CI: 1.01-2.72; OR = 1.97, 95 % CI: 1.36-2.85; OR = 2.48, 95 % CI: 1.50-4.11; OR = 2.71, 95 % CI: 1.06-6.95, respectively). In particular, HPV16E7 was related to cancer of floor of mouth, oral cavity NOS and palate (OR = 2.71, 95 % CI: 1.06-6.95; OR = 3.32, 95 % CI:1.53-7.19; OR = 3.34, 95 % CI:1.38-8.06). Results were inconsistent for HPV18 due to low prevalence of infection. Our study suggests that HPV16 infection may increase the risk of developing floor of mouth, gum, tongue, and palate cancers. Subjects with HPV infection have a higher risk of cancer from all sites of the oral cavity.

Sections du résumé

BACKGROUND
The aim of this study was to investigate the relationship between high-risk genotypes of Human Papilloma Virus (HPV) and cancer of different subsites of the oral cavity.
MATERIAL AND METHODS
A pooled analysis of five studies included on the International Head and Neck Cancer Epidemiology (INHANCE) Consortium was conducted. HPV 16 and HPV 18 were considered. Adjusted odds ratios (ORs) and corresponding 95 % confidence intervals (CIs) for HPV and each oral cavity subsites were simultaneously estimated using multinomial logistic regression models.
RESULTS
The analysis included 1157 cases and 3272 controls. This study showed a slightly higher prevalence of HPV infection among oral cancer cases than controls. In particular, an increased risk of other and not otherwise specified (NOS) sites within the oral cavity, oral tongue, palate and floor of mouth cancer was observed for overall HPV16 positivity (OR = 1.66, 95 % CI: 1.01-2.72; OR = 1.97, 95 % CI: 1.36-2.85; OR = 2.48, 95 % CI: 1.50-4.11; OR = 2.71, 95 % CI: 1.06-6.95, respectively). In particular, HPV16E7 was related to cancer of floor of mouth, oral cavity NOS and palate (OR = 2.71, 95 % CI: 1.06-6.95; OR = 3.32, 95 % CI:1.53-7.19; OR = 3.34, 95 % CI:1.38-8.06). Results were inconsistent for HPV18 due to low prevalence of infection.
CONCLUSION
Our study suggests that HPV16 infection may increase the risk of developing floor of mouth, gum, tongue, and palate cancers.
CLINICAL RELEVANCE
Subjects with HPV infection have a higher risk of cancer from all sites of the oral cavity.

Identifiants

pubmed: 34509873
pii: S1877-7821(21)00137-5
doi: 10.1016/j.canep.2021.102020
pii:
doi:

Types de publication

Journal Article Meta-Analysis Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

102020

Subventions

Organisme : NCI NIH HHS
ID : R03 CA113157
Pays : United States
Organisme : NIDCR NIH HHS
ID : R03 DE016611
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA048996
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA012609
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA011979
Pays : United States
Organisme : NIDCR NIH HHS
ID : R01 DE013110
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA078609
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA100679
Pays : United States

Informations de copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.

Auteurs

Luca Giraldi (L)

Institute of Public Health, Catholic University of Sacred Heart, Rome, Italy.

Giulia Collatuzzo (G)

Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.

Dana Hashim (D)

Norwegian Institute of Public Health, Department of Genetics and Bioinformatics, Oslo, Norway; Norwegian Institute of Public Health, Center of Fertility and Health, Oslo, Norway.

Silvia Franceschi (S)

Scientific Directorate, Aviano Oncologic Center (CRO) IRCCS, Aviano, Italy.

Rolando Herrero (R)

International Agency for Research on Cancer, Lyon, France.

Chu Chen (C)

Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

Stephen M Schwartz (SM)

Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

Elaine Smith (E)

College of Public Health, University of Iowa, Iowa City, IA, USA.

Karl Kelsey (K)

Brown University, Providence, RI, USA.

Michael McClean (M)

Boston University School of Public Health, Boston, MA, USA.

Maura Gillison (M)

Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA.

Stefania Boccia (S)

Institute of Public Health, Catholic University of Sacred Heart, Rome, Italy.

Mia Hashibe (M)

Division of Public Health, Department of Family and Preventive Medicine, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT, USA.

Yuan-Chin Amy Lee (YC)

Division of Public Health, Department of Family and Preventive Medicine, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT, USA.

Paolo Boffetta (P)

Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy; Stony Brook Cancer Center, Stony Brook University, Stony Brook, NY, USA. Electronic address: paolo.boffetta@stonybrookmedicine.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH